News

In a new study entitled “Metabotropic P2Y1 receptor signaling mediates astrocytic hyperactivity in vivo in an Alzheimer’s disease mouse model” published in Nature Communications, Andrea Delekate and colleagues examined the astrocytic network underlying pathways that may be implicated in Alzheimer’s disease (AD), and provide solid evidence for…

Biopharmaceutical company Anavex Life Sciences Corp. recently presented encouraging results from their phase 1 clinical trial, a study testing the company’s lead investigational oral treatment for Alzheimer’s disease, Anavex 2-73, at CNS Summit 2014 in Boca Raton, Florida. After assessing the drug’s safety and effectiveness, the medication…

In a recent study entitled “Pharmacological chaperones stabilize retorter to limit APP processing,” the authors report that pharmacologic chaperones have a highly positive impact on a multiprotein complex — the retromer — that has been linked to Alzheimer’s disease. The study was published in the April issue…

In neurodegenerative disorders such as Alzheimer’s Disease, the loss of memory is often a defining symptom. In a study entitled “FASTKD2 is associated with memory and hippocampal structure in older adults” the authors report to have found a new genetic variant in the FASTKD2 gene that is associated with…

In a recent study entitled “Longitudinal PET-MRI reveals β-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion” the authors developed a new imaging protocol that allows detection and examination of Alzheimer’s Disease typical beta-amyloid plaques. The study was published in the online issue of…